AI Article Synopsis
- Recent findings from 2022 for rheumatoid arthritis (RA) management emphasize the importance of customizing treatment based on individual patient characteristics and response to medications.
- Research into biomarkers and remote care applications highlights the shift towards precision medicine and a more patient-centered approach in treating RA.
- Updated guidelines from new vaccination developments and literature also impact the management of RA-related issues, such as interstitial lung disease and pregnancy.
Article Abstract
New evidence from 2022 slightly changed some perspectives for rheumatoid arthritis (RA) management. Real-world data on the efficacy and safety of disease-modifying anti-rheumatic drugs strengthened the importance of tailoring treatment decisions based on patient characteristics. Moreover, the research of response biomarkers to therapy underlined the need for precision medicine and remote care applications showed an innovative outlook that supports a patient-centred approach. New developments in vaccinations led to the release of updated guidelines and to a consistent improvement in the prevention of vaccine-preventable infections. New literature data also reconsidered drug management in RA-associated interstitial lung disease and pregnancy. In this paper, the reviewers aim to present the most relevant studies published during the last year in the field of RA management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.55563/clinexprheumatol/nat8nl | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An effective strategy with tofacitinib for the management of focal myositis with rheumatoid arthritis: a case report.
Front Immunol
December 2024
Department of Rheumatology and Immunology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.
Focal myositis is a rare, localized, benign, self-limiting, and non-suppurative inflammatory lesion of the skeletal muscle that may occasionally occur as a complication of rheumatic diseases. This case report discusses a 58-year-old patient with rheumatoid arthritis, who was diagnosed with focal myositis during standard immunosuppressive therapy. The patient was treated with tofacitinib; to our knowledge, this is the first reported case of focal myositis managed with this medication.
View Article and Find Full Text PDFYoga as an adjunctive therapy for rheumatoid arthritis.
Cochrane Database Syst Rev
January 2025
Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effect and safety of yoga as an adjunctive therapy for rheumatoid arthritis.
View Article and Find Full Text PDFRole of Non-coding RNAs in Rheumatoid Arthritis and Supervision Mechanism of Chinese Medicine.
Chin J Integr Med
January 2025
Department of Rheumalogy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, China.
The prevalence of rheumatoid arthritis (RA) has sharply increased in recent years, posing a serious threat to human health. RA is characterized as a chronic, multisystem disease with morning stiffness and symmetric small joint pain. However, its fundamental processes are poorly understood.
View Article and Find Full Text PDFSilencing aquaporin 1 inhibits autophagy to exert anti-rheumatoid arthritis effects in TNF-α-induced fibroblast-like synoviocytes and adjuvant-induced arthritis rats : Names of authors.
Inflamm Res
January 2025
Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, China.
Objective: Fibroblast-like synoviocytes (FLS) are key players in rheumatoid arthritis (RA) by resisting apoptosis via increased autophagy. Elevated synovial aquaporin 1 (AQP1) affects RA FLS behaviors, but its relationship with FLS autophagy is unclear. We aim to clarify that silencing AQP1 inhibits autophagy to exert its anti-RA effects.
View Article and Find Full Text PDFRegulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib.
Sci Rep
January 2025
Nordic Bioscience, Immunoscience, Herlev Hovedgade 205-207, Herlev, 2730, Denmark.
Understanding how inflammatory cytokines influence profibrogenic wound healing responses in fibroblasts is important for understanding the pathogenesis of fibrosis. TNF-α and IL-13 are key cytokines in Th1 and Th2 immune responses, respectively, while TGF-β1 is the principal pro-fibrotic mediator. We show that 12-day fibroblast culture with TNF-α or IL-13 induces fibrogenesis, marked by progressively increasing type III and VI collagen formation, and that TGF-β1 co-stimulation amplifies these effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!